Headquarters: One Baxter Parkway
Baxter International is a global healthcare company which helps in the treatment of complex medical conditions including hemophilia, immune disorders, kidney disease, cancer, trauma and other conditions.
Baxter has two main business segments:
Baxter is a leading manufacturer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines.
Baxter's Medical Products business manufactures products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, Baxter's Medical Products business is a leader in Renal home-based therapies, such as peritoneal dialysis, and offers other products and services for people with end-stage kidney disease.
In 2011, Baxter reported revenues of $13.89 billion, an 8% increase, and net income of $2.22 billion. Baxter spent $946 million on research and development in 2011.
"2011 was a very successful year for Baxter as we continue to fulfill our mission of providing innovative life-saving and life-sustaining therapies that advance patient care worldwide," said Robert Parkinson, Chairman and CEO. "I'm pleased that despite a challenging, global macro-economic environment, our company delivered strong financial and operational performance, while accelerating investments in innovation, advancing our new product pipeline and pursuing other initiatives to enhance long-term growth, while returning significant value to our shareholders."
The U.S. Food and Drug Administration (FDA) recently approved the use of ADVATE for routine prophylaxis to prevent and reduce the frequency of bleeding episodes in patients with hemophilia A. ADVATE is the only antihemophilic factor approved in the United States for prophylactic use in both adults and children.
Baxter has 19,000 employees in the U.S.
1931 - The company is founded as the first manufacturer of commercially prepared intravenous solutions.
1933 - During its first two years, the company distributed products manufactured by another company in Los Angeles owned by Dr. Don Baxter. But as demand grew in the Midwest, the need for a more central manufacturing base became apparent. In 1933, the company opened its first manufacturing facility in a renovated automobile showroom in Glenview, Illinois. There, six employees turned out the complete line of five solutions in glass containers.
1935 - The young company prospered and its products earned a reputation for safety and effectiveness, giving physicians new confidence in intravenous therapy. Dr. Ralph Falk purchased Dr. Baxter´s interest in the company. He also developed an research-and-development function that was the beginning of the company's pioneering advances in medical technology. Strong commitment to R&D continues today as the key to the company´s product development efforts.
1961 - Baxter stock began trading on the New York Stock Exchange
1979 - The company introduces the first automated blood-cell separator, the CS-3000 system.
1985 - Baxter acquires American Hospital Supply Corporation, becoming a broad-based health-care products distributor in addition to a developer of medical technologies.
Baxter compensation includes base salary and bonus pay and stock options.
- Medical coverage
- A company-paid pension plan after one year of service
Updated March 11, 2012